AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn’s disease drugs Skyrizi and Rinvoq.
Source link
AbbVie Revenue Rises on Immunology Growth
Date:
More like thisRelated
BHP Flags $2.3 Billion Potash Write-Down as Costs Rise
The miner expects another cost overrun on a Canadian...
OF Wenceel Perez injured in face in training room accident
Jun 17, 2026, 07:28 PM ETHOUSTON -- Detroit Tigers...
Way beyond a social media ban, one town in Ireland is raising kids without smartphones
Overlooking the Irish Sea just...
Pentagon chief lashes out at NATO allies and announces a review of US forces in Europe
U.S. Defense Secretary Pete Hegseth lashed out at NATO...